For instance, we found that the targeting of DNMT in combination with SI-12 was effective across all the cancer types that we have tested, which highlights the potential of DNMTs as therapeutic targets in combination with SRC-3 inhibition, likely expanding the clinical application for DNMT inhibitors beyond hematologic malignancies91,92. The gene discussed is DNMT1; the disease is cancer.